stockportfolio.pro
Stocks / PRCT vs SLS
PRCT vs SLS
PROCEPT BioRobotics Corporation and SELLAS Life Sciences Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| PROCEPT BioRobotics Corporation (PRCT) | SELLAS Life Sciences Group, Inc. (SLS) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $308.05M | $0 |
| Net income (latest FY) | $-95.57M | $-26.86M |
| Revenue growth (5y CAGR) | 109.0% | — |
| Net margin | -31.0% | — |
| Return on equity | -26.1% | -37.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PRCT — free Open SLS — freeFrequently asked questions
Which is bigger, PRCT or SLS?
PROCEPT BioRobotics Corporation is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, PRCT or SLS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.